Friday 6 November 2026 Export BMY’s income statement to Excel — free account

Bristol Myers Squibb Company

BMY Healthcare Drug Manufacturers General

Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.

Revenue: +6.93%
EPS: −2.02%
Free cash flow: −36.0%
Total debt: −12.5%

Quarter to September 2026, against a year earlier

62.62 0.51 −0.81%

Follow BMY

Alert me

Market cap: $129.0B
P/E: 14.0×
Fwd P/E: 11.9×
Dividend yield: 3.99%
F-score: 8/9
Altman Z: 2.14
Beneish M: −2.69
Dividend safety: 63/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Bristol Myers Squibb Company (BMY) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Bristol Myers Squibb Company (BMY) trades at a price to free cash flow of 13.9×. Over the past ten years it has ranged from 5.7× (October 2025) to 382× (June 2016); the current reading is higher than 64% of that period. That is below the Drug Manufacturers General industry median of 21.3× and below the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BMY/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Bristol Myers Squibb Company price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BMY/metrics/price-to-free-cash-flow">Bristol Myers Squibb Company (BMY) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	8.5×	3.87%
FY2024	8.2×	(4.70%)
FY2023	8.6×	(33.02%)
FY2022	12.9×	41.71%
FY2021	9.1×	(13.69%)
FY2020	10.5×	(29.04%)
FY2019	14.8×	6.92%
FY2018	13.9×	(41.92%)
FY2017	23.9×	(55.66%)
FY2016	53.9×	(39.60%)

Period	Price to free cash flow	Change
Sep 2026	13.7×	33.48%
Jun 2026	10.3×	(0.92%)
Mar 2026	10.4×	21.53%
Dec 2025	8.5×	42.34%
43 more quarters	Free account

Against its own ten years

Low 5.7× High 382×

Ten-year median 12.0×

Current reading's percentile 64

Company	Price to free cash flow
SNY Sanofi compare	6.7×
GSK GSK PLC Sponsored ADR compare	11.4×
BMY Bristol Myers Squibb Company	13.9×
GILD Gilead Sciences, Inc. compare	15.1×
PFE Pfizer Inc. compare	15.5×
NVS Novartis AG compare	21.7×
NVO Novo Nordisk A/S compare	23.5×
AMGN Amgen Inc. compare	27.3×
AZN AstraZeneca PLC compare	45.8×
Drug Manufacturers General industry median	21.3×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Bristol Myers Squibb Company (BMY) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BMY

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on BMY

Stockrow Weekly